In the same study, syngeneic mice transplanted with murine leukemia cells expressing MLL-AF9 were either left untreated or were treated with doxorubicin plus cytarabine, the PARP inhibitor BMN673, or the combination of the two. The gene discussed is KMT2A; the disease is leukemia.